$Merck & Co (MRK.US)$ The FDA is somewhat cautious. Japan ha...

The FDA is somewhat cautious. Japan has set a timetable and will decide whether to ratify the deal on Thursday. Personally, I think it should be approved. After all, the mechanism is different. If the virulence of the virus is reduced, this easily available oral drug would be better. If it becomes more virulent, Pfizer's alone may not be enough. Two will never do. Three shots. Singapore is on its fourth injection.) If toxicity increases, oral drug cocktails are definitely on the agenda. And the second Pfizer did not reach the clinical end point, there was no improvement in symptoms, there was no cure, there was a reduction in the risk of hospitalization, and over time, who knows what happens over time?